References
- Henderson C, Canellos GP. Cancer of the breast, the past decade. N Engl J Med 1980; 302: 1–30.
- Breast Cancer Chemotherapy Consensus Conference. JAMA 1985; 254: 3461–3463.
- Ashford AR, Donev I, Tiwari RP et al. Reversibile ocu-lar toxicity related to tamoxifen therapy. Cancer 1988; 61: 33–35.
- Griffiths MFP. Tamoxifen retinopathy at low dosage. Am J Ophthalmol 1987; 104 (2): 185–186.
- Pugesgaard T, von Eyben FE. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer 1986; 58: 383–386.
- Bertelli G, Ponzato P, Amoroso D et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988; 12: 307–310.
- Goodnough LT, Pearson OH. Adjuvant therapy for breast cancer. N Eng J Med 1988; 319 (7): 443.
- Jordan CV, Phelps E, Lingren JU. Effects of antiestro-gens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10: 31–35.
- Turner RT, Wakeley JK, Hammon KS et al. Tamoxifen prevents the skeletal effects of ovarian deficiency in rats. J Bone Miner Res 1988; 2: 449–456.
- Love RR, Mazees RB, Tormey DC et al. Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 1988; 12: 297–301.
- Turken S, Sins E, Seldin E et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989; 81: 1086–1088.
- Boccardo F, Guarneri D, Rubagotti A et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984; 70: 61–68.
- Gottardis MM, Robinson SP, Satyaswaroop PG et al. Contrasting action of tamoxifen on endometrial and breast tumor growth in athymic mouse. Cancer Res 1988; 48: 812–815.
- Anzai Y, Holinka CF, Kuramoto H et al. Stimulatory effects of 4-0H tamoxifen on proliferation of human endometrial adenocarcinoma cell (Ishikawa like). Cancer Res 1989; 49: 2362–2365.
- Fornander T, Rutquist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer. Lancet 1989; i: 117-120.
- Assikis VJ, Neven P, Jordan VC et al. A realistic clini-cal perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A: 1464–1476.
- DeWaard F, Wang DV. Epidemiology and prevention: Workshop Report. Eur J Cancer Clin Oncol 1988; 24: 45-48. Boccardo F, Rubagotti A, Bruzzi P et al. Chemotherapy vs tamoxifen vs chemotherapy plus tamoxifen in node posi-tive, estrogen receptor positive breast cancer pts. Results of a multicentric Italian study. J Clin Oncol 1988; 8: 1310–1320.
- Lerner LJ, Jordan CV. Development of antiestrogens and their use in breast cancer. Cancer Res 1990; 50: 4177–4189.
- Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; ii: 282-286.
- Patterson JB, Battersby LA. Tamoxifen: clinical pharmacology, safety and clinical development. In: Cchemotherapeutic effects of nolvadex: tamoxifen citrate. I. C. Allegra (ed), McGraw Hill, New York, 1981: 20.
- Martoni A, Pannuti F. A comparative appraisal of hor-mone therapy tolerability in anti-oestrogens in oncology: past, present and prospects. F Pannuti ( ed), Excepta Medica, Amsterdam, 1985: 98-112.
- Bilimora MM, Assikis VJ, Jordan VC et al. Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 1996; 2: 140–150.
- Robustelli della Cuna G, Preti P, Sica G. Antiestrogeni. In: Terapia endocrina del carcinoma mammario, EMS-Pavia, 1993: 127-148.
- Wallgren A, Baral E, Carstensen J et al: Should adju-vant tamoxifen be given for several years in breast cancer? In: Jones SE ( ed) Adjuvant therapy of cancer IV. Grune and Stratton, New York, 1984: 331-337.
- Early Breast Cancer Trials Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 26: 1681–1692.
- Goldhirsch A, Gelber RD, Mouridsen HT. Adjuvant chemotherapy in premenopausal pts: a more complicated form of ophorectomy. In: Cavalli ( ed) Endocrine therapy of breast cancer II. Springer-Verlag, Berlin 1987: 11-20.
- Boccardo F. Attuali orientamenti e prospettive nella endocrinoterapia adiuvante del carcinoma mammario. Minerva Med, Torino, 1988.
- UKBCTCS/UICC/WHO. Breast cancer trials review meeting. Washington DC, September 1985.
- Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996; 88: 1791-1793.
- Boccardo F, Guarneri D, Torrisi R. Endocrinoterapia adiuvante del carcinoma mammario. In: Endocrinologia e endocrinoterapia del carcinoma mammario. SSOSB, Genova, 1991: 121-141.